Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 72 points (0.5%) at 14,749 as of Thursday, April 25, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,049 issues advancing vs. 833 declining with 158 unchanged. The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.7%. Top gainers within the industry include Icon ( ICLR), up 9.2%, Zimmer Holdings ( ZMH), up 1.6%, Stryker Corporation ( SYK), up 1.4%, Becton Dickinson ( BDX), up 1.4% and Edwards Life ( EW), up 1.4%. A company within the industry that fell today was Aetna ( AET), up 0.97. TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today: 5. Covidien ( COV) is one of the companies pushing the Health Services industry higher today. As of noon trading, Covidien is up $0.37 (0.56) to $66.67 on average volume Thus far, 847,565 shares of Covidien exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $66.37-$66.76 after having opened the day at $66.44 as compared to the previous trading day's close of $66.30. Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $31.5 billion and is part of the health care sector. The company has a P/E ratio of 17.0, below the S&P 500 P/E ratio of 17.7. Shares are up 15.4% year to date as of the close of trading on Wednesday. TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.